Alberto Hernández-Sánchez

Dr. Alberto Hernández-Sánchez

Hematology, Hospital Universitario de Salamanca, Salamanca, Castille-Leon, Spain
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
Alberto Hernández-SánchezAlberto Hernández-Sánchez
Alberto Hernández-Sánchez
TGTeresa González
Teresa González
MSMarta Sobas
Marta Sobas
ESEric Sträng
Eric Sträng
Gastone CastellaniGastone Castellani
Gastone Castellani
LBLars B. Bullinger
Lars B. Bullinger
Balanced rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the prognostic impact of different fusion partners. Moreover, prognostic implications of gene mutations co-occurring with KMT2Ar are not established. From the HARMONY AML database 205 KMT2Ar adult patients were selected, 185 of whom had mutational information by a panel-based next-generation sequencing analysis. Overall survival (OS) was similar across the different translocations, including t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However, independent prognostic factors for OS in intensively treated patients were age >60 years (HR 2.1, p = 0.001), secondary AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with de novo AML < 60 years, KRAS and TP53 were the prognostically most relevant mutated genes, as patients with a mutation of any of those two genes had a lower complete remission rate (50% vs 86%, p < 0.001) and inferior OS (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic stem cell transplantation in first complete remission was able to improve OS (p = 0.003). Our study highlights the importance of the mutational patterns in adult KMT2Ar AML and provides new insights into more accurate prognostic stratification of these patients.

14 January 2026 in Leukemia
Verified
Journal Article
Open access
PDF file
Alberto Hernández-SánchezAlberto Hernández-Sánchez
Alberto Hernández-Sánchez
ÁVÁngela Villaverde-Ramiro
Ángela Villaverde-Ramiro
ESEric Sträng
Eric Sträng
ATAmin T. Turki
Amin T. Turki
MAMaría Abáigar
María Abáigar
LBLars B. Bullinger
Lars B. Bullinger
NPM1 -mutated ( NPM1 -mut) acute myeloid leukemia (AML) is generally associated with a more favorable outcome, although the presence of additional gene mutations can influence patient prognosis. We analyzed intensively-treated adult NPM1 -mut AML patients included in the HARMONY Alliance database. A newly developed risk classification, which included combinations of co-mutations in FLT3 -ITD, DNMT3A , IDH1/IDH2 , and TET2 genes, was applied to a training cohort of NPM1 -mut AML patients included in clinical trials ( n = 1001), an internal validation cohort more representative of real-world settings ( n = 762), and an external validation cohort enrolled in UK-NCRI trials ( n = 585). The HARMONY classification considered 51.8% of the NPM1 -mut AML training cohort patients as favorable, 24.8% as intermediate, and 23.4% as adverse risk, with median overall survival (OS) of 14.4, 2.2, and 0.9 years, respectively; p < 0.001), thereby reclassifying 42.7% of NPM1 -mut patients into a different European LeukemiaNet (ELN) 2022 risk category. These results were confirmed both in an internal and external validation cohort. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) showed the highest benefit in the NPM1 -mut adverse-risk subgroup. The HARMONY classification provides the basis for a refined genetic risk stratification for adult NPM1 -mut AML with potential clinical impact on allo-HSCT decision-making.

1 February 2022 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
JGJosé Ramón González-Porras
José Ramón González-Porras
MBMoncef Belhassen-Garcia
Moncef Belhassen-Garcia
ABAmparo Lopez Bernus
Amparo Lopez Bernus
LVLuis Mario Vaquero-Roncero
Luis Mario Vaquero-Roncero
BRBeatriz Rodríguez-Alonso
Beatriz Rodríguez-Alonso
JMJosé-Ángel Martín-Oterino
José-Ángel Martín-Oterino
The intensity of the thromboprophylaxis needed as a potential factor for preventing inpatient mortality due to coronavirus disease-19 (COVID-19) remains unclear. To explore the association between anticoagulation intensity and COVID-19 survival. Retrospective observational study in a tertiary-level hospital in Spain. Low-molecular-weight heparin (LMWH) status was ascertained based on prescription at admission. To control for immortal time bias, anticoagulant use was analyzed as a time-dependent variable. 690 patients were included (median age, 72 years). LMWH was administered to 615 patients, starting from hospital admission (89.1%). 410 (66.7%) received prophylactic-dose LMWH; 120 (19.5%), therapeutic-dose LMWH; and another 85 (13.8%) who presented respiratory failure, high D-dimer levels (> 3 mg/l) and non-worsening of inflammation markers received prophylaxis of intermediate-dose LMWH. The overall inpatient-mortality rate was 38.5%. The anticoagulant nonuser group presented higher mortality risk than each of the following groups: any LMWH users (HR 2.1; 95% CI: 1.40-3.15); the prophylactic-dose heparin group (HR 2.39; 95% CI, 1.57-3.64); and the users of heparin dose according to biomarkers (HR 6.52; 95% CI, 2.95-14.41). 3.4% of the patients experienced major hemorrhage. 2.8% of the patients developed an episode of thromboembolism. This observational study showed that LMWH administered at the time of admission was associated with lower mortality among unselected adult COVID-19 inpatients. The magnitude of the benefit may have been greatest for the intermediate-dose subgroup. Randomized controlled trials to assess the benefit of heparin within different therapeutic regimes for COVID-19 patients are required.

30 January 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
Alberto Hernández-SánchezAlberto Hernández-Sánchez
Alberto Hernández-Sánchez
ÁVÁngela Villaverde‐Ramiro
Ángela Villaverde‐Ramiro
EAEduardo Arellano-Rodrigo
Eduardo Arellano-Rodrigo
MGMarta Garrote
Marta Garrote
IMIván Martín
Iván Martín
T(the Spanish MPN Group (GEMFIN)
the Spanish MPN Group (GEMFIN)

17 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JAJosgrey del Valle Navas Acosta
Josgrey del Valle Navas Acosta
Alberto Hernández-SánchezAlberto Hernández-Sánchez
Alberto Hernández-Sánchez
TGTeresa González
Teresa González
ÁVÁngela Villaverde-Ramiro
Ángela Villaverde-Ramiro
SSSandra Santos
Sandra Santos
Jesús María Hernández-RivasJesús María Hernández-Rivas
Jesús María Hernández-Rivas
Adult B-cell acute lymphoblastic leukemia (B-ALL) is characterized by genetic heterogeneity and a high relapse rate, affecting over 40% of adults. However, the mechanisms leading to relapse in adults are poorly understood. Forty-four adult B-ALL patients were studied at both diagnosis and relapse by next-generation sequencing (NGS). Four main genetic pathways leading to relapse in adults were identified: IKZF1plus genetic profile, RAS mutations and TP53 alterations in Ph-negative B-ALL and acquisition of ABL1 mutations in Ph-positive patients. The most frequently deleted gene at diagnosis was IKZF1 (52%), and 70% of these patients had IKZF1plus profile. Notably, 88% of patients with IKZF1plus at diagnosis retained this genetic profile at relapse. Conversely, the acquisition of RAS mutations or the expansion of subclones (normalized variant allele frequency < 25%) present from diagnosis were observed in 24% of Ph-negative patients at relapse. In addition, 24% of relapses in the Ph-negative cohort could potentially be driven by TP53 alterations. Of these cases, five presented from diagnosis, and four emerged at relapse, mostly as “double-hit” events involving both TP53 deletion and mutation. In Ph-positive B-ALL, the main genetic finding at relapse was the acquisition of ABL1 mutations (86%). Three clonal evolution patterns were identified: the persistent clone trajectory (25%), the expanding clone trajectory (11%) and the therapy-boosted trajectory (48%). Our results reveal the presence of preferential biological pathways leading to relapse in adult B-ALL. These findings underscore the need for personalized therapeutic strategies to improve clinical outcomes in adult patients with B-ALL.

20 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ATAmin T. Turki
Amin T. Turki
YFYi Fan
Yi Fan
Alberto Hernández-SánchezAlberto Hernández-Sánchez
Alberto Hernández-Sánchez
WSWellington Silva
Wellington Silva
SFShaun Fleming
Shaun Fleming
MEMerlin Engelke
Merlin Engelke
Despite advances for patients with acute leukemia health disparities limit access to diagnosis and treatment. Artificial Intelligence (AI) approaches may address some disparities. We retrospectively assemble a diverse, international cohort of 6206 leukemia patients from 20 centers to test an AI tool designed to support leukemia diagnosis using standard laboratory results. Executing the pretrained algorithm results in varying accuracy metrics. With confidence cutoff predictions, 2000-fold bootstrapped area under the curve (AUROC) metrics are 0.94 for acute myeloid leukemia (AML), 0.98 for the promyelocytic subtype and 0.84 for acute lymphoblastic leukemia. However, this cutoff excludes 70.8–92.5% of patients from predictions. We improve accuracy and robustness, while maintaining generalizability via an ensemble of Isolation Forest and Local Outlier Factor increasing AUROC for AML from 0.72 to 0.84 (hold-out test set, patients below confidence threshold), while excluding only 12.1% of patients. Furthermore, we retrain the algorithm for pediatric patients.